8-K: Semler Scientific Q2 2025: Bitcoin Holdings Soar, Revenue Dips

Semler Scientific reported a significant increase in Bitcoin holdings and unrealized gains in Q2 2025, despite a 43% year-over-year decrease in healthcare revenues.

Summary

• Revenues for the second quarter ended June 30, 2025, were $8.2 million, representing a 43% decrease year-over-year.
• Total operating expenses for Q2 2025 were $10.3 million, up from $9.1 million in Q2 2024.
• The company reported a loss from operations of $2.1 million in Q2 2025, compared to income from operations of $5.4 million in Q2 2024.
• Pre-tax income for Q2 2025 was $80.6 million, significantly higher than $1.1 million in Q2 2024, primarily due to an $83.8 million unrealized gain from the change in fair value of Bitcoin holdings.
• Net income for Q2 2025 was $66.9 million, or $5.04 per diluted share, compared to $11 thousand, or $0.00 per diluted share, in Q2 2024.
• As of July 31, 2025, total Bitcoin holdings reached 5,021 Bitcoins with a fair value of $586.2 million.
• Since the first quarter, approximately $195.4 million of Bitcoin was purchased.
• Year-to-date through July 31, 2025, the Bitcoin treasury strategy generated over $110.4 million in unrealized gains and delivered a 31.3% BTC yield.
• The company launched CardioVanta, a wholly-owned subsidiary focused on future healthcare initiatives for early detection of heart failure and cardiac arrhythmia.
• Under a new At-the-Market (ATM) offering program, 4,932,737 shares of common stock were sold for aggregate net proceeds of approximately $194.3 million through July 31, 2025.
• An initial ATM program sold 2,438,274 shares for aggregate net proceeds of approximately $126.0 million.
• A litigation contingency of $29.75 million related to a proposed settlement agreement with the U.S. Department of Justice (DOJ) was accrued.

Sentiment

Score: 7

Explanation: While core healthcare revenue declined and operations incurred a loss, the substantial unrealized gains from the Bitcoin treasury strategy and aggressive capital raises for further Bitcoin acquisition present a strong positive for investors focused on that strategy, leading to a high net income. The dual-engine strategy is a bold move.

Positives

• Significant increase in Bitcoin holdings to 5,021 BTC with a fair value of $586.2 million as of July 31, 2025.
• Generated over $110.4 million in unrealized gains year-to-date through July 31, 2025, from the Bitcoin treasury strategy.
• Achieved a 31.3% BTC yield year-to-date through July 31, 2025.
• Reported a net income of $66.9 million in Q2 2025, primarily driven by Bitcoin fair value changes.
• Appointment of Natalie Brunell to the board of directors and hiring of Joe Burnett as Director of Bitcoin Strategy deepens connection to the Bitcoin community.
• Launch of CardioVanta, a new wholly-owned subsidiary, positions the company for future healthcare initiatives focused on early detection of heart failure and cardiac arrhythmia.

Negatives

• Revenues decreased by 43% year-over-year to $8.2 million in Q2 2025.
• Reported a loss from operations of $2.1 million in Q2 2025, a significant decline from income from operations of $5.4 million in Q2 2024.
• Total operating expenses increased to $10.3 million from $9.1 million year-over-year.
• Incurred $0.5 million in legal expenses related to the proposed DOJ settlement.
• Customer concentration risk, with two largest customers comprising 45% and 31% of Q2 2025 revenues.

Risks

• Risks inherent with investing in Bitcoin, including Bitcoin's volatility.
• Risk of implementing a Bitcoin treasury strategy.
• Risk that insurance plans and other customers will not continue to license its cardiovascular testing products or license new FDA-cleared products and services.
• Risk of changes in the reimbursement landscape for its customers, including related to the Centers for Medicare and Medicaid Services (CMS) rate announcement.
• Risk of obtaining a new 510(k) clearance for expanded indications for QuantaFlo.
• Risks related to reaching a final settlement with the DOJ, including the risk that DOJ will file a complaint seeking in excess of the agreed amount if unable to agree on final settlement terms.
• Risks related to Semler Scientific's indebtedness.

Future Outlook

Semler Scientific intends to strategically accumulate Bitcoin using proceeds from equity and debt financings, as well as cash flows from operations. The company plans to drive long-term value in its healthcare business through its new subsidiary, CardioVanta, focusing on early detection of heart failure and cardiac arrhythmia. Additionally, it aims to seek a new 510(k) clearance for its flagship product, QuantaFlo, with expanded indications, and is working towards a final settlement with the U.S. Department of Justice.

Management Comments

• "We have made excellent progress with our Bitcoin treasury strategy." Eric Semler, Executive Chairman.
• "We purchased approximately $195.4 million of Bitcoin since the first quarter, bringing the value of our total holdings to nearly $586.2 million as of July 31, 2025." Eric Semler, Executive Chairman.
• "Year-to-date through July 31, 2025, this strategy has generated more than $110.4 million in unrealized gains and delivered a 31.3% BTC yield." Eric Semler, Executive Chairman.
• "We also deepened our connection to the Bitcoin community by appointing Natalie Brunell to our board of directors and hiring Joe Burnett as director of Bitcoin strategy." Eric Semler, Executive Chairman.
• "During the quarter, we were very pleased to launch CardioVanta, a wholly owned subsidiary that will drive our future healthcare initiatives focused on early detection of heart failure and cardiac arrhythmia." Doug Murphy-Chutorian, MD, CEO.
• "We believe CardioVanta positions us to deliver long-term value in our healthcare business as we continue to aggressively execute on our Bitcoin treasury strategy establishing Semler Scientific as a dual-engine platform for growth." Doug Murphy-Chutorian, MD, CEO.

Industry Context

Semler Scientific is pursuing a unique 'dual-engine platform for growth' strategy, combining its traditional medical device business with a significant Bitcoin treasury reserve asset strategy. This positions the company as one of the few publicly traded entities to heavily integrate Bitcoin into its corporate treasury, aligning with a nascent trend of corporate digital asset adoption. In its healthcare segment, the launch of CardioVanta signifies a strategic focus on chronic disease management, particularly heart failure and cardiac arrhythmia, which are areas of increasing medical and economic importance.

Comparison to Industry Standards

• Semler Scientific's adoption of Bitcoin as a primary treasury reserve asset places it alongside MicroStrategy as a leading corporate holder of Bitcoin, distinguishing it from most traditional companies.
• The reported 31.3% BTC yield year-to-date through July 31, 2025, reflects strong performance in its Bitcoin treasury strategy, comparable to the appreciation seen in Bitcoin's market value during the period.
• The 43% year-over-year decrease in healthcare revenues to $8.2 million suggests underperformance compared to growth trends in many specialized medical device or diagnostic sectors, which often see single to double-digit growth.
• The shift to a loss from operations of $2.1 million in Q2 2025 from a profit of $5.4 million in Q2 2024 for its core healthcare business indicates significant operational challenges or strategic re-prioritization away from traditional revenue generation.

Management Changes

Legal Proceedings

• Proposed settlement agreement with the U.S. Department of Justice (DOJ) pertaining to a civil investigative demand.
• Incurred $0.5 million of legal expenses related to the proposed DOJ settlement.
• A litigation contingency of $29.75 million was accrued.
• Risk that DOJ will file a complaint seeking in excess of the agreed amount if unable to agree on final settlement terms.

Stakeholder Impact

• Shareholders: Significant unrealized gains from Bitcoin holdings could increase shareholder value, but declining core healthcare revenues and operational losses present a risk. The ATM offering dilutes existing shareholders but funds the Bitcoin strategy.
• Customers: Potential impact from changes in reimbursement landscape and customer concentration. Launch of CardioVanta aims to provide new healthcare solutions.
• Creditors: Risks related to Semler Scientific's indebtedness are mentioned.

Next Steps

• Continue to aggressively execute on the Bitcoin treasury strategy.
• Drive future healthcare initiatives through CardioVanta, focusing on early detection of heart failure and cardiac arrhythmia.
• Seek a new 510(k) clearance for QuantaFlo with expanded indications.
• Reach a final settlement with the U.S. Department of Justice regarding the civil investigative demand.
• Host a live video webinar on August 4, 2025, at 4:30 p.m. ET to discuss results and provide a business update.
• Maintain and update the Bitcoin dashboard on its website as a disclosure channel for material nonpublic information.

Key Dates

Recommendation

The company's financial performance is bifurcated: its traditional healthcare business is struggling with declining revenues and operating losses, while its Bitcoin treasury strategy is generating substantial unrealized gains and driving overall net income. This creates a complex investment profile. The aggressive accumulation of Bitcoin, funded by significant capital raises (ATM offerings and convertible notes), indicates a strong commitment to this new strategy, which has been highly profitable so far. However, the inherent volatility of Bitcoin and the operational challenges in the core business introduce considerable risk. For a seasoned investor, the Bitcoin play offers speculative upside, but the underlying business weakness suggests caution. A 'hold' recommendation acknowledges the potential for continued Bitcoin-driven gains while signaling concerns about the core business and the high-risk nature of the treasury strategy.

Keywords

Bitcoin, BTC, Healthcare, Medical Devices, Cardiovascular, Peripheral Arterial Disease, QuantaFlo, Treasury Strategy, Digital Assets, NASDAQ, SMLR, Financial Results, Q2 2025, ATM Offering